View solutions

Partnerships are sought with end-users interested in helping to validate the BLB-Test, a portable, automated assay for detecting BoNT as a replacement for the mouse lethality bioassay (MLB).

Partners are sought to validate GentleSharp™, a system for small volume blood sampling.

ETT S.p.A is looking for partners in the agrochemical, pharmaceutical and chemical sectors to help validate their model of rat primary cortical neurons on MEA neurochips, for assessing neurotoxicity in vitro.

Partners interested in applying Primetech’s micro infusion implantable pumps to their research and drug discovery programs are sought, to uncover novel applications, optimise exposure profiles and to improve the accuracy and translational relevance of the results achieved.

Aptasol are seeking partners interested in adopting or helping to develop their aptamers (synthetic single stranded oligonucleotides) to replace the use of traditional animal-derived antibodies.

Actual Analytics Ltd seek partners interested in trying their innovative rodent home cage analysis system that provides 24/7 monitoring of rodent behaviours in a group-housed environment.

ZeClinics seek collaborators that can provide small compound sets or expert guidance to help develop ZeGlobalTox, a preclinical zebrafish embryo screen to identify multiple organ toxicity in the same animal.

Physiomics is seeking partners to help calibrate Virtual Tumour Clinical, an in silico model of human tumour cell populations for optimising drug treatment regimens in clinical cancer studies.

EBERS is looking for collaborators that are able to provide cancer cultures and compounds with preclinical/ clinical data to validate their microfluidic cell culture device

INOVOTION are seeking partners able to provide novel reagents or compounds with preclinical/clinical data available to test their chick egg chorioallantoid membrane assay for anticancer drug development.

Ostara seeks collaborators skilled in embryo transfer, to help compare the efficiency of Ostara pessaries with the use of vasectomised males.

Professor Andrew Nelson is seeking partners to help develop and validate his model of biomembrane activity, which can be used to identify chemicals and drugs with potential biomembrane permeability and toxicity.

Midas Mediscience Ltd is seeking collaborators to help extend the utility of DrugPrint®, a novel, multicellular, human cardiac tissue model for predictive ion channel profiling and cardiotoxicity screening.

Professor Susan Barnett is seeking industry or academic partners to provide novel compounds with preclinical/clinical data available, to assess the utility of her in vitro spinal cord injury model to identify potentially efficacious enhancers of CNS repair.

Lein Applied Diagnostics is seeking partners to utilise their novel technology for making non-invasive pharmacokinetics (PK) measurements both in vivo and in vitro.

Dr Tamer Mohammed is seeking pharmaceutical/chemical industry partners to provide access to a compound library to validate his human embryonic bodies assay as a standard model of screening for teratogenicity.